V. Richter: "The low toxicity and originality of the pharmaceutical agent are its major advantages"

Cover Page

Cite item


There is no question that the government needs to provide vigorous financial support to Russian researchers looking to design new drugs. A different question is to what extent should the government participate in the financing and at
what point should industrial investors join in?

About the authors

V. A. Richter

Institute of Chemical Biology and Fundamental Medicine, SB RAS

Author for correspondence.
Email: actanaturae@gmail.com
Russian Federation

Copyright (c) 2012 Richter V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies